210 related articles for article (PubMed ID: 21561860)
1. Bim protein degradation contributes to cisplatin resistance.
Wang J; Zhou JY; Wu GS
J Biol Chem; 2011 Jun; 286(25):22384-92. PubMed ID: 21561860
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.
Kawabata T; Tanimura S; Asai K; Kawasaki R; Matsumaru Y; Kohno M
J Biol Chem; 2012 Mar; 287(13):10289-10300. PubMed ID: 22270368
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells.
Abutin RM; Chen J; Lung TK; Lloyd JA; Sawyer ST; Harada H
Exp Hematol; 2009 Feb; 37(2):151-8. PubMed ID: 19100675
[TBL] [Abstract][Full Text] [Related]
4. BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells.
Yuan Z; Wang F; Zhao Z; Zhao X; Qiu J; Nie C; Wei Y
PLoS One; 2011; 6(5):e20586. PubMed ID: 21655183
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death.
Li Z; Zhang J; Liu Z; Woo CW; Thiele CJ
Cell Death Differ; 2007 Feb; 14(2):318-26. PubMed ID: 16778834
[TBL] [Abstract][Full Text] [Related]
6. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.
Hazlehurst LA; Argilagos RF; Dalton WS
Br J Haematol; 2007 Jan; 136(2):269-75. PubMed ID: 17233818
[TBL] [Abstract][Full Text] [Related]
7. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
8. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
[TBL] [Abstract][Full Text] [Related]
9. EGFR signaling defines Mclâ»1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
10. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
11. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
12. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
Kong LR; Chua KN; Sim WJ; Ng HC; Bi C; Ho J; Nga ME; Pang YH; Ong WR; Soo RA; Huynh H; Chng WJ; Thiery JP; Goh BC
Mol Cancer Ther; 2015 Jul; 14(7):1750-60. PubMed ID: 25939760
[TBL] [Abstract][Full Text] [Related]
13. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S
Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843
[TBL] [Abstract][Full Text] [Related]
14. Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons.
Meller R; Cameron JA; Torrey DJ; Clayton CE; Ordonez AN; Henshall DC; Minami M; Schindler CK; Saugstad JA; Simon RP
J Biol Chem; 2006 Mar; 281(11):7429-36. PubMed ID: 16431916
[TBL] [Abstract][Full Text] [Related]
15. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
Chakraborty AR; Robey RW; Luchenko VL; Zhan Z; Piekarz RL; Gillet JP; Kossenkov AV; Wilkerson J; Showe LC; Gottesman MM; Collie NL; Bates SE
Blood; 2013 May; 121(20):4115-25. PubMed ID: 23532732
[TBL] [Abstract][Full Text] [Related]
16. Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells.
Wang J; Zhou JY; Zhang L; Wu GS
Cell Cycle; 2009 Oct; 8(19):3191-8. PubMed ID: 19755862
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
Li C; Li R; Grandis JR; Johnson DE
Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
[TBL] [Abstract][Full Text] [Related]
18. PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells.
Chen K; Tu Y; Zhang Y; Blair HC; Zhang L; Wu C
J Biol Chem; 2008 Feb; 283(5):2508-17. PubMed ID: 18063582
[TBL] [Abstract][Full Text] [Related]
19. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C
Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869
[TBL] [Abstract][Full Text] [Related]
20. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]